Children in England with high-risk neuroblastoma will now be offered a cancer drug that could extend their life.
A researcher explains an early stage clinical trial testing the potential of a new type of immunotherapy to treat neuroblastoma.
A number of cancer clinical trials involving immunotherapy treatments appear to be showing promise, according to new research.
Our scientists have discovered that neuroblastoma cells can produce a cellular ‘kryptonite’ that seems to sap the power from nearby immune cells.
Cancer cells in neuroblastoma release a molecule that breaks down a key energy source for the body’s immune cells, leaving them too drained to fight the disease
Read Professor Andy Pearson’s story, exploring his career researching childhood cancer and what the future holds for the BEACON neuroblastoma trial.
A simple blood test could pinpoint which children are unlikely to respond to treatment for a particularly aggressive form of neuroblastoma
Neuroblastoma is a type of childhood cancer and our researchers are pioneering new clinical trials to tackle aggressive forms of the disease – how does it work?
Cancer Research UK scientists and paediatric cancer specialists have launched the BEACON-neuroblastoma trial, which aims to find the best chemotherapy regimen for children and young adults with recurring or resistant neuroblastoma. Researchers will also investigate whether blocking the growth of new blood vessels supplying the tumours can enhance this treatment.